Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | GLA | P06280 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.34 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3352688 | 0.85 | TSHR (0.37) | TSHRKDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL3354708 | 0.82 | MAOA (0.33) | MAOB | |
| Dihydrocoumarin SCHEMBL8888209 | 0.74 | MAOB (0.48) | TSHRKDM4ECYP1A2GLACYP2C9 | |
| Dihydrocoumarin SCHEMBL17629427 | 0.71 | MAOB (0.50) | TSHRKDM4ECYP1A2GLACYP2C9 | |
| Dihydrocoumarin SCHEMBL29350292 | 0.71 | MAOB (0.50) | TSHRKDM4ECYP1A2GLACYP2C9 | |
| Dihydrocoumarin SCHEMBL28795 | 0.71 | MAOB (0.50) | TSHRKDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL3358107 | 0.71 | MAOA (0.36) | MAOB | |
| SCHEMBL11194900 | 0.70 | GAA (0.33) | — | |
| Dihydrocoumarin SCHEMBL7617919 | 0.69 | MAOB (0.48) | TSHRKDM4ECYP1A2GLACYP2C9 | |
| SCHEMBL102103 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017107052-A1 | SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2017-06-29 | — | — | WO | disclosed |
| US-9382224-B2 | 7-acyloxychromen-4-one derivatives and the use thereof as self-tanning substances | MERCK PATENT GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20130287716-A1 | 7-ACYLOXYCHROMEN-4-ONE DERIVATIVES AND THE USE THEREOF AS SELF-TANNING SUBSTANCES | MERCK PATENT GMBH (DE) | 2013-10-31 | — | — | US | disclosed |
| US-7696195-B2 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-04-13 | — | — | US | disclosed |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130287716-A1 | 7-ACYLOXYCHROMEN-4-ONE DERIVATIVES AND THE USE THEREOF AS SELF-TANNING SUBSTANCES | TYR, CYP7B1, CYP46A1 | TSHR 3071/4885KDM4E 1212/4885CYP1A2 54/4885 |
| US-20050256099-A1 | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | CALCRL, CALCR, CALCA | TSHR 436/4885KDM4E 4579/4885CYP1A2 969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.